UNCY
NASDAQUnicycive Therapeutics Inc.
Price$3.36-0.13 (-3.72%)
01:30 PM07:45 PM
News · 26 weeks42+600%
2026-04-192026-10-11
Mix1490d
- SEC Filings4(29%)
- Insider3(21%)
- Other3(21%)
- Market2(14%)
- Earnings1(7%)
- Leadership1(7%)
Latest news
25 items- NEWSUNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action DeadlineNEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Submit your information. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.UNCY closed at $7.70 on June 29, 2026. The next morning, shares fell $3.01, or 39.1%, to close at $4.69 on unusually heavy trading volume. Lead plaintiff applications must be submitted by November 2, 2026.Why the June 30 Announcement Allegedly Mattered to ShareholdersOn June 30, 2026, before the marke
- NEWSUNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact Levi & KorsinskyNEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP alerts investors in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.UNCY closed at $7.70 on June 29, 2026, the day before the disclosure; the Class Period high close was $8.56 per share on May 14, 2026. The following morning, shares fell $3.01, or 39.1%, to close at $4.69 on unusually heavy trading volume. To be considered for lead plaintiff, invest
- INSIDERSEC Form 3 filed by new insider Manning Meredith3 - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- PRUnicycive Therapeutics Appoints Meredith Manning to Board of DirectorsMOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. "We are very pleased to welcome Meredith to our Board of Directors. Her extensive commercialization experience, track record of building successful biopharmaceutical organizations, and leadership through successful product launches will be invaluable to Unicycive," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. "We look forward to benefiting from Mere
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum CarbonateResubmission of NDA includes Chemistry, Manufacturing, and Controls (CMC) data from a new drug product manufacturing vendor The resubmission package includes 12 months of OLC drug product stability data from the new manufacturing vendor Company anticipates FDA acceptance of the NDA within 30 days of resubmission; new assigned PDUFA date expected to be 6 months from resubmissionCurrent cash position allows runway into 2H 2027 MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the resubmission of its
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceLOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET. A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor - FDA has assigned a facility inspection to third-party manufacturing vendor of OLC - As of June 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $61.4 million, with expected runway into 2027 MOUNTAIN VIEW, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the second quarter ended June 30, 2026, and provided a business up
- SECSEC Form 10-Q filed by Unicycive Therapeutics Inc.10-Q - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Kenkare-Mitra Sara4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Laumas Sandeep4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.SCHEDULE 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- PRUnicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)-- Complete Response Letter relates to deficiencies previously identified at third-party manufacturing vendor -- -- FDA inspection of third-party facility did not occur during the NDA resubmission review -- -- Labeling discussions currently underway; latest communication received by the Company from FDA on June 29 regarding carton and container label -- -- FDA did not raise concerns regarding the clinical efficacy or safety data of OLC, and no additional data was requested -- MOUNTAIN VIEW, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced th
- SECSEC Form DEFA14A filed by Unicycive Therapeutics Inc.DEFA14A - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECUnicycive Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- SECSEC Form EFFECT filed by Unicycive Therapeutics Inc.EFFECT - Unicycive Therapeutics, Inc. (0001766140) (Filer)
- INSIDERAmendment: SEC Form 4 filed by CEO Gupta Shalabh K.4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Kenkare-Mitra Sara4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Laumas Sandeep4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by EVP, Pharmaceuticals and BD Gupta Pramod4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by CFO Townsend John4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
UNCY FAQ
7 questionsWhat does Unicycive Therapeutics Inc. do?
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Where does UNCY stock trade?
Unicycive Therapeutics Inc. (UNCY) is listed on NASDAQ.What sector and industry is UNCY in?
Unicycive Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Unicycive Therapeutics Inc. go public?
Unicycive Therapeutics Inc. (UNCY) completed its IPO in 2021.What are analysts saying about UNCY?
Unicycive Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $2200.00 price target on 2026-05-01. Recent price targets range from $600.00 to $2200.00.What companies are similar to UNCY?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare UNCY side-by-side with any of them on Quantisnow.How can I track UNCY on Quantisnow?
Quantisnow aggregates Unicycive Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UNCY to receive live email and push alerts on every new disclosure.